How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens fare in the long-term?

Pier Luigi Zinzani, Maurizio Martelli, Massimo Magagnoli, Francesco Zaja, Sergio Storti, Enzo Pavone, Vito Michele Lauta, Amalia De Renzo, Marco Gobbi, Monica Bocchia, Fioravante Ronconi, Laura Scaramucci, Filippo Gherlinzoni, Francesca Palombi, Maurizio Bendandi, Vittorio Stefoni, Paola Anticoli Borza, Claudia Cellini, Franco Mandelli, Sante Tura

Research output: Contribution to journalArticle

Abstract

Background and Objectives. To examine the long-term clinical course and prognostic factors of patients with advanced aggressive non-Hodgkin's lymphoma (NHL) treated with third-generation regimens as front-line chemotherapy. Design and Methods. A total of 348 patients aged

Original languageEnglish
Pages (from-to)996-1001
Number of pages6
JournalHaematologica
Volume84
Issue number11
Publication statusPublished - Nov 1999

Keywords

  • Aggressive NHL
  • F-MACHOP
  • Late relapses
  • Long-term outcome
  • MACOP-B

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens fare in the long-term?'. Together they form a unique fingerprint.

  • Cite this

    Zinzani, P. L., Martelli, M., Magagnoli, M., Zaja, F., Storti, S., Pavone, E., Lauta, V. M., De Renzo, A., Gobbi, M., Bocchia, M., Ronconi, F., Scaramucci, L., Gherlinzoni, F., Palombi, F., Bendandi, M., Stefoni, V., Borza, P. A., Cellini, C., Mandelli, F., & Tura, S. (1999). How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens fare in the long-term? Haematologica, 84(11), 996-1001.